Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Illumina Inc (ILMN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,066,060
  • Shares Outstanding, K 147,000
  • Annual Sales, $ 2,752 M
  • Annual Income, $ 726,000 K
  • 36-Month Beta 0.97
  • Price/Sales 17.47
  • Price/Cash Flow 61.44
  • Price/Book 14.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.24
  • Number of Estimates 11
  • High Estimate 1.41
  • Low Estimate 1.11
  • Prior Year 1.11
  • Growth Rate Est. (year over year) +11.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
287.85 +13.21%
on 07/30/18
341.08 -4.46%
on 08/07/18
+20.39 (+6.67%)
since 07/17/18
3-Month
261.61 +24.57%
on 05/29/18
341.08 -4.46%
on 08/07/18
+57.43 (+21.39%)
since 05/17/18
52-Week
189.15 +72.29%
on 08/18/17
341.08 -4.46%
on 08/07/18
+134.68 (+70.44%)
since 08/17/17

Most Recent Stories

More News
4 Winning Stocks With Solid Efficiency Level

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

SRDX : 73.45 (+0.55%)
ILMN : 325.88 (-0.34%)
VRTX : 176.08 (+0.64%)
MDR : 18.46 (+2.16%)
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

LGND : 247.98 (+3.47%)
ILMN : 325.88 (-0.34%)
MNK : 34.69 (+1.61%)
EVOK : 2.44 (+3.39%)
Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

ITGR : 71.45 (+0.92%)
ILMN : 325.88 (-0.34%)
ARAY : 3.88 (+10.07%)
ISRG : 524.92 (+0.19%)
Illumina Inc Shares Up 33.2% Since SmarTrend's Buy Recommendation (ILMN)

SmarTrend identified an Uptrend for Illumina Inc (NASDAQ:ILMN) on April 16th, 2018 at $245.46. In approximately 4 months, Illumina Inc has returned 33.21% as of today's recent price of $326.98.

ILMN : 325.88 (-0.34%)
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

ILMN : 325.88 (-0.34%)
GILD : 72.92 (-3.53%)
INO : 4.43 (-1.56%)
REGN : 374.26 (+0.67%)
Illumina to Offer $650 Million Convertible Senior Notes

Illumina, Inc. (Nasdaq: ILMN) today announced its intention to offer, subject to market and other conditions, approximately $650 million aggregate principal amount of convertible senior notes...

ILMN : 325.88 (-0.34%)
Can Illumina (ILMN) Stock Continue to Grow Earnings?

Illumina (ILMN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

ILMN : 325.88 (-0.34%)
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

CELG : 90.37 (+0.24%)
LGND : 247.98 (+3.47%)
ILMN : 325.88 (-0.34%)
GILD : 72.92 (-3.53%)
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

CORT : 12.92 (+3.36%)
CELG : 90.37 (+0.24%)
ILMN : 325.88 (-0.34%)
PFE : 42.09 (+1.62%)
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

ILMN : 325.88 (-0.34%)
PBYI : 41.90 (-1.76%)
GILD : 72.92 (-3.53%)
RHHBY : 30.1200 (+0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ILMN with:

Business Summary

Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications...

See More

Key Turning Points

2nd Resistance Point 332.31
1st Resistance Point 329.10
Last Price 325.88
1st Support Level 323.39
2nd Support Level 320.89

See More

52-Week High 341.08
Last Price 325.88
Fibonacci 61.8% 283.04
Fibonacci 50% 265.11
Fibonacci 38.2% 247.19
52-Week Low 189.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar